| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Arthritis and Asthma Research Program, The Garvan Institute of Medical Research, Sydney,
Cooperative Research Center for Asthma, Sydney,
Centenary Institute of Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia; and
Department of Research, Biogen Idec Inc., Cambridge, MA 02142
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
BAFF binds to several receptors. These include transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), BAFF-R (BR3), and B cell maturation Ag (BCMA) (13, 14, 15, 16, 17). Another TNF family member termed a proliferation-inducing ligand (APRIL) also binds to TACI and BCMA (14, 18). BAFF-R appears to be particularly important for the regulation of B cell survival and maturation in the spleen, because A/WySnJ mice expressing a defective BAFF-R have disrupted B cell maturation, similar to that seen in BAFF-deficient mice (17, 19). The BCMA receptor appears not to play a role in B cell maturation but is involved in plasma cell survival (20). In TACI-deficient mice, there are increased B cell numbers, marked splenomegaly, and mice develop autoimmune disorders (21). Antigenic challenge in these mice results in enhanced Ab production (21). Because an agonistic mAb to TACI inhibited B cell proliferation, signaling through TACI may in fact serve to down-regulate B cell activity (21).
BAFF and possibly APRIL also act on T cells. In vitro studies of human T cells showed that BAFF provided a complete costimulatory signal together with anti-TCR stimulation (22, 23). In mice, a TACI-Fc fusion protein blocked activation of T cells in vitro, and inhibited T cell priming in vivo (24). Also, treatment with TACI-Fc substantially inhibited inflammation, as well as bone and cartilage destruction, in a mouse model of rheumatoid arthritis (24). T cells from transgenic mice that overexpressed human APRIL showed greatly enhanced survival in vitro and in vivo (25). In autoimmune patients, inappropriate costimulation of T and B cells by BAFF may be an important component of disease pathogenesis. The receptor for BAFF on T cells is largely unknown, although one study reported TACI expression on a subset of activated T cells using a polyclonal Ab (26). Expression of BCMA and BAFF-R is thought to be restricted to B cells (16, 17, 27, 28).
The critical functions of BAFF for B and T cell biology are facilitated by the regulated expression of BAFF receptors. Accordingly, we have investigated the capacity of BAFF to stimulate B and T cells, and have used specific antagonistic mAbs as well as strains of mice with mutant BAFF receptors to ascertain precise expression patterns and functional roles for the three receptors.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Soluble forms of human BAFF and BAFF receptors were supplied by Apotech (Epalinges, Switzerland) and P. Schneider (Institute of Biochemistry, BIL Biomedical Research Center, University of Lausanne, Epalinges, Switzerland). Denatured BAFF controls were prepared by incubation at 95°C for 2 h. Unconjugated and FITC-, PE-, CyChrome-, PerCP-, PE-Cy7-, allophycocyanin-Cy7- and allophycocyanin-conjugated mAbs to various cell surface markers were from BD Biosciences (San Diego, CA), with the exception of CCR7-FITC (R&D Systems, Minneapolis, MN). Immunofluorescent staining was performed using standard procedures with appropriate secondary staining reagents (Jackson ImmunoResearch Laboratories, West Grove, PA), and cells were analyzed using BD FACSCalibur or LSRII flow cytometers (BD Biosciences). Six-color flow cytometric analysis to assess BAFF-R expression on naive and memory subsets of CD4+ and CD8+ cells used anti-human BAFF-R (h.BAFF-R) biotin (mAb 9-1) and streptavidin-PE, anti-CCR7-FITC, anti-CD3-PerCP, anti-CD45RO-allophycocyanin, anti-CD4-PE-Cy7, and anti-CD8-allophycocyanin-Cy7. A biotinylated mIgG1 (BD Pharmingen, San Diego, CA) was used as an isotype control for the BAFF-R Ab.
Animals, lymphocyte preparations, and T and B cell stimulations
All human and mouse experiments were performed with approval of St. Vincent’s campus human or animal ethics committees. Human PBMCs were isolated from human blood by Ficoll gradient centrifugation. Human splenocytes or tonsil cells were obtained from resected human spleen or tonsil, and were prepared by gentle teasing with forceps. Human CD3+ T cells were isolated from PBMC preparations by magnetic separation (MACS; Miltenyi Biotec, Sydney, Australia). CD3+ cells were then isolated in a magnetic field, to >98% purity. For human B cell stimulation, PBLs were incubated in 96-well plates (105 cells/well in 100 µl RPMI 1640 supplemented with 10% FBS) for 48 h with 75 ng/ml soluble BAFF in the presence of 5 µg/ml goat F(ab')2 anti-human µ-chain Ab (Jackson ImmunoResearch Laboratories), and with different concentrations of anti-h.BAFF-R mAb, h.BAFF-R-Fc, or human IgG (hIgG) control (29).
Homozygous TACI–/– mice were generated as previously described for targeting the BAFF and BCMA loci (30). Briefly, a tailless human CD2 reporter cDNA was inserted in frame at the ATG that normally initiates TACI translation and just upstream of a phosphoglycerate kinase 1-promoted neomycin resistance cassette. The resulting deletion of the TACI genomic locus spanned 6.12 kb of DNA immediately downstream of the initiating ATG. This mutation introduced premature stop codons in the three possible reading frames downstream of the CD2 reporter and eliminated all the nucleotides encoding aa 1–89 of normal mouse TACI (GenBank accession number NM_021349). The A/WySnJ mouse strain (17) was obtained from The Jackson Laboratory (Bar Harbor, ME). Mouse CD3+ cells were isolated from spleen via magnetic separation using Pan T cell isolation kit (MACS; Miltenyi Biotec). For mouse B cell proliferation assays, B cells were isolated from spleens of 2-mo old C57BL/6 mice using B cell recovery columns (Accurate Chemical & Scientific, Westbury, NY). Mouse B cells were incubated in 96-well plates (105 cells/well in 50 µl RPMI 1640 supplemented with 10% FBS) for 72 h with 75 ng/ml BAFF (Biogen Idec, Cambridge, MA), in the presence of 2 µg/ml goat anti-mouse µ-chain Ab (Jackson ImmunoResearch Laboratories), and with the indicated concentrations of previously described reagents, including polyclonal hIgG (Novartis Pharmaceuticals, East Hanover, NJ), h.BCMA-Fc, or anti-mouse BAFF-R (m.BAFF-R) mAbs (29). For Ag-specific T cell assays, splenic T cells from DO11.10 TCR transgenic mice were purified by magnetic separation, and 5 x 104 cells/well were cultured with 1 x 105 cells/well of mitomycin C-inactivated APC, together with OVA peptide in 96-well U-bottom plates. BAFF costimulation of T cells was performed by adding 4 µg/ml soluble BAFF or denatured BAFF to wells. For inhibition assays, cells were cultured with anti-m.BAFF-R mAbs (2 µg/ml), h.BCMA-Fc, or hIgG (2 µg/ml).
For anti-CD3 T cell proliferation assay, human T cells were activated using plate-bound anti-human CD3 mAb (mAb TR66), and mouse T cells were activated with anti-mouse-CD3 mAb 145-2C11 (BD Pharmingen). Anti-CD3 mAb and BAFF were coated onto plates overnight in PBS at 4°C either separately or in combination, followed by two PBS washes. A total of 2 x 106 PBMC (human) or CD3+ (human or mouse) cells/ml were added to tissue culture plates containing immobilized anti-CD3 ± plate-bound or soluble BAFF, and harvested after 72 h. For all mouse and human proliferation measurements, cultures were pulsed with [3H]thymidine (1 µCi/well) 18 h before harvesting and quantified using a beta-scintillation counter.
Production and specificity of mAbs to human and mouse BAFF receptors
An expression DNA construct containing the human TACI cDNA sequence was kindly provided by P. Schneider, and a human BAFF-R expression construct was developed using the p-Tracer vector, as per manufacturer’s protocol (Invitrogen, Mt. Waverley, Australia). Cell surface receptor-expressing transfectants were made using the rat basophilic leukemia (RBL) mast cell line (human and mouse TACI, mouse BAFF-R), or mouse B cell lymphoma L1.2 cells (human BAFF-R). Anti-h.TACI mAb 1A1 (rat IgG1) was generated by immunizing Wistar rats with 2 x 107 irradiated TACI-transfected RBL cells, 6 times at 2-wk intervals. Cell fusion was performed as described (31). Similarly, anti-h.BAFF-R mAb 11C1 (mouse IgG1) was generated using the same procedures except that BAFF-R-L1.2 transfectants were used to immunize C57BL/6 mice. In addition, anti-h.BAFF-R (clone 9-1) and hamster anti-human BCMA (clone C4E2.2) mAbs were used. These were generated by immunizing with receptor-Ig fusion proteins, as detailed previously (28). The rat anti-mouse TACI mAbs, 8F10 (IgG2a) and 5L7 (IgG1), were generated by immunizing Wistar rats with soluble TACI extracellular domain protein, 6 times at 2-wk intervals. Anti-m.BAFF-R mAbs B2G1 and P1B8 were produced by immunizing hamsters with murine BAFF-R-Fc protein. Rat anti-m.BAFF-R mAbs 7H22-E16 and 3I4 (both IgG1) were produced by immunizing Wistar rats with soluble m.BAFF-R-Fc protein, 5 times at 2-wk intervals.
For immunohistochemical visualization of BAFF-R expression, Ag retrieval was performed by immersing 4-µM-thick paraffin sections of palatine tonsil in an EDTA-based retrieval solution (pH 9.0) and heating for 20 min at 95–99°C in a water bath. After cooling, sections were immunostained using a DakoCytomation Autostainer (DakoCytomation, Carpinteria, CA); following 5 min incubation with 3% hydrogen peroxide, sections were incubated sequentially for 30 min with anti-BAFF-R mAb (11C1) and Mouse EnVision+ HRP (DakoCytomation). Anti-BAFF-R binding was visualized using Liquid diaminobenzidine+ (DakoCytomation).
GeneChip microarray analysis (Affymetrix, Millenium Science, Victoria, Australia), and real-time LightCycler PCR (Roche Molecular Biochemicals, Sydney, Australia)
Total RNA was isolated from harvested cells using Qiagen RNeasy Total RNA Isolation kit (Valencia, CA). Total RNA (2 µg) was then used for cDNA synthesis, with 4.5 U AMV reverse transcriptase and MgCl2-containing buffer (Promega, Madison, WI), 20 nmol dNTPs (Promega), and 0.02 nmol oligo-p(dT)15 primer (Roche Molecular Biochemicals) and incubated at 42°C for 90 min. cDNA was used for LightCycler PCR (Roche Molecular Biochemicals) with the LightCycler FastStart Master SYBR Green I kit (Roche Molecular Biochemicals), using 3 mM MgCl2 and 0.5 µM individual primers with the following specific protocol: 10 min 95°C activation of FastStart TaqDNA polymerase (Roche Molecular Biochemicals), and 40 cycles of 95°C for 15 s, 63°C for 5 s, and 72°C for 21 s. The primers used were a combination of original sequences designed using Primer3 (http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). LightCycler analyses used the crossing point data for each gene during the logarithmic amplification program. The crossing point for each gene in each sample was normalized to the crossing point of GAPDH. Respective genes were then compared between two samples and expressed as a fold change.
For GeneChip assessment of transcript expression, cRNA was preparedusing the methods as described (32). Hybridization to the Affymetrix U133A and B GeneChips and subsequent scanning and analysis was conducted exactly according to Affymetrix protocols. GeneChip analyses included human Th1 and Th2, purified eosinophils, cultured mast cells, IgE-activated mast cells, purified neutrophils, and splenic memory B cells. A full description of the preparation of these cells, and access to the full GeneChip results, is available at http://www.garvan.unsw.edu.au/public/microarrays.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
mAbs were raised to human TACI, BAFF-R, and BCMA, and to mouse TACI and BAFF-R, to determine the functional significance of these three receptors for B and T cells, and to determine their precise expression pattern. Various immunization strategies were used, including receptor fusion proteins and transfectants expressing high levels of these receptors. All of the ensuing mAb raised against either human or mouse BAFF-R or TACI stained their respective receptor transfectants (Fig. 1, A and B) or reacted specifically against receptor-Ig fusion proteins by ELISA (Fig. 1C), without cross-reacting with the other BAFF receptors. The specificity of a mAb raised against human BCMA-Fc, C4E2.2, has been reported previously (28). Anti-human BAFF-R mAb 9-1 blocked BAFF binding to BAFF-R expressing cells (data not shown). Similarly, anti-murine BAFF-R mAb B2G1 was blocking, while mAb P1B8 was nonblocking (see below).
|
mAb to mouse BAFF-R stained the vast majority of mouse splenic B cells (CD4-negative cells, Fig. 2A) and lymph node B cells (data not shown). A few resting T cells were clearly BAFF-R+ (Fig. 2A) and PCR analysis of mouse T cells and T cell lines revealed expression of BAFF-R and absence of TACI and BCMA (data not shown). In experiments using BAFF costimulation of anti-µ-mediated B cell proliferation, an antagonistic mAb to mouse BAFF-R blocked proliferation to the same level as did the positive control BCMA-Fc (Fig. 2B), indicating that in mice, BAFF-R is the principal costimulatory BAFF receptor for resting mature B cells.
|
BAFF costimulation of T cells in mice is mediated by BAFF-R
We next assessed BAFF responses by mouse T cells, using an OVA peptide-specific proliferation by DO11.10 TCR transgenic mouse T cells. Fig. 3A shows that an antagonistic mAb recognizing murine BAFF-R (mAb B2G1) inhibited T cell proliferation by 
20%, indicating that endogenous BAFF participates in T cell costimulation, for an optimal response (Fig. 3A), as previously shown by others (23). As a control, BCMA-Fc inhibited proliferation to the same extent. Furthermore, addition of exogenous soluble BAFF also increased T cell proliferation in the presence of APC (Fig. 3B). The effects of BAFF on B cells in mice occur, at least in part, through the up-regulation of the survival factor Bcl-2 (33, 37). Bound BAFF, but not denatured BAFF, also resulted in an up-regulation of Bcl-2 in purified mouse T cells suboptimally stimulated for 72 h with anti-CD3 (Fig. 3C).
|
BAFF-R is the predominant BAFF receptor expressed on human blood B cells
The studies described above established BAFF-R as the predominant BAFF receptor for mouse B and T cells. The expression pattern of BAFF-R, BCMA, and TACI was also assessed on subsets of blood and tonsil B cells in humans. On blood B cells, BAFF-R was expressed at a high level on all CD19+ B cells, whereas BCMA was absent (Fig. 4A). TACI was expressed, but only on a proportion of blood B cells, and at a much lower level than BAFF-R. We confirmed that BAFF-R was also the principal stimulatory receptor for human blood B cells, by inhibition of BAFF costimulation of anti-µ-treated blood B cells using a blocking mAb to BAFF-R. Fig. 4B shows that anti-BAFF-R mAb 9-1, which interferes with binding of BAFF to BAFF-R, inhibited BAFF costimulation of B cells. A proportion of these B cells did express low levels of TACI (Fig. 4A); however, TACI is known to repress B cell activation, and TACI is dispensable for BAFF stimulation of B cell responses to anti-µ (21).
|
The staining of human tonsil cells with mAbs to BAFF-R, BCMA, and TACI revealed that BAFF-R was also the predominant receptor expressed on tonsil B cells. Nevertheless, BAFF-R did show a variation in staining intensity between different B cell subsets (Fig. 5A). B cells with a GC phenotype (CD38+, CD27+, CD39–, CD24–, and IgM–) expressed lower levels of BAFF-R, and this was clearly evident through immunohistochemical staining of B cell follicles in tonsil (Fig. 5B). In contrast to the blood, where no B cells expressed BCMA, a proportion of tonsil B cells did express low levels, and multicolor flow cytometry revealed that these BCMA+ B cells displayed a phenotype consistent with GC B cells (Fig. 5A). Strikingly, TACI and BCMA were expressed on different subsets of the CD19+ B cell population, with the TACI+ subset being CD38–, CD27–, CD39+, CD24+, and IgM+ (i.e., a non-GC phenotype). The distinct difference between the TACI+ and BCMA+ subsets was further illustrated by a direct two-color analysis (Fig. 5C), which showed that the vast majority of BCMA+ B cells were TACI–; this was particularly evident when B cell blasts were gated and analyzed (Fig. 5C).
|
BAFF has been reported to costimulate T cell responses in humans (22), as well as in mice (see above). However, mAb staining suggested that TACI and BCMA were absent from human blood T cells, and that BAFF-R was expressed at very low levels (Fig. 6A). To further define the precise expression pattern of the receptors, particularly BAFF-R, a sensitive multicolor flow cytometric analysis was performed using a BD LSRII or FACSCalibur. All human T cell populations examined, including blood T cells, in vitro anti-CD3-activated T cells (24 and 48 h, data not shown), and tonsillar T cells were found to be consistently negative for BCMA and TACI (Fig. 6A, and data not shown). In contrast, a fraction of T cells expressed BAFF-R, especially T cells activated for 72 h with anti-CD3 (Fig. 6A). This led us to examine expression of BAFF-R on naive, central memory, and effector memory CD4+ and CD8+ cells as defined using the markers CCR7 and CD45RO. Expression of BAFF-R was determined for the various populations and is represented by different shaded profiles, as indicated (Fig. 6B). BAFF-R was expressed predominantly by central and effector memory T cells, and not naive T cells, in keeping with the up-regulation of BAFF-R on activated T cells.
|
Costimulatory effects of BAFF on human T cell proliferation
Similar to the mouse results and previous study in humans (22), BAFF increased cell proliferation of suboptimally anti-CD3-treated human T cells, to a level similar to that observed with anti-CD28 stimulation (Fig. 7A). However, we observed that the ability of BAFF to costimulate human T cell responses was variable, and was highly dependent on T cell purity. We next used Ig fusion proteins of TACI, BCMA, and BAFF-R to block BAFF (and APRIL) activity in a suboptimal anti-CD3 T cell activation assay (Fig. 7B). All three fusion proteins inhibited T cell proliferation in response to anti-CD3, demonstrating the importance of endogenous BAFF for normal T cell stimulation. Neutralization of BAFF rather than APRIL appeared to be responsible for the observed effect, because BAFF-R-Fc (BAFF specific) reduced proliferation to the same extent as TACI-Fc or BCMA-Fc. Although it has been reported BCMA-Fc has a lower affinity for BAFF (29), we found all three fusion proteins showed a similar ability to block BAFF activity, presumably because these fusion proteins were used at high concentrations (30 µg/ml). We did observe a degree of person to person variation, as TACI-Fc failed to inhibit T cell proliferation in one individual of five (data not shown). In addition, unlike the mouse experiments described above, anti-h.BAFF-R mAb (2–30 µg/ml used) failed to inhibit T cell proliferation, suggesting that the way BAFF-R signals in B and T cells is different and possibly activated by a different interaction between BAFF and BAFF-R.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The role of BAFF-R in peripheral B cell survival and costimulation has been difficult to gauge using BAFF-R mutant mice, because splenic B cell maturation is halted at the T1 stage (17). As BAFF-R was the only known BAFF receptor detectable on most mature resting B cells, and anti-BAFF-R mAbs completely inhibited BAFF-mediated costimulation of B cells, we conclude that positive BAFF responses up to the stage of CD38+ plasmablasts occur exclusively through this receptor. An assessment of BCMA and TACI deficient mice supports this conclusion. Early studies with BCMA-deficient mice found no unusual phenotype (30, 40, 41), although recent studies showed impaired survival of long-lived bone marrow plasma cells (20). Our expression analysis also showed that BCMA is most likely relevant for later stages of B cell maturation or survival, i.e., for CD38+ plasmablasts (28) and GC B cells (this report). BCMA is also up-regulated on mouse plasma cells (20). Likewise, TACI was expressed only weakly on a small subset of peripheral B cells. TACI-deficient mice showed increased B cell numbers, and splenomegaly (Refs. 21 , 34 , 35 , and this report). TACI has been proposed to play a role as a negative regulator for B cells, rather than as an essential survival-related receptor (21). However, TACI may play an important role in some aspects of B cell maturation or function within the spleen, because T2 and MZ B cells expressed high levels of TACI. MZ B cells are essential for T-independent immune responses (42), and TACI knockout mice have impaired T-independent but normal T-dependent responses (34). TACI was clearly dispensable for splenic B cell maturation, as shown by the production of mature B cells in TACI–/– mice. Nevertheless, BAFF (or APRIL) signaling through TACI at the T2 or MZ stages may constrain B cell proliferation at critical stages of tolerance induction. The T1-T2 maturation step is likely an important immune tolerance checkpoint for maturing B cells (43). The MZ has been suggested as a refuge for autoreactive B cells (44, 45), and increased TACI expression facilitating repression of B cell proliferation might help contain autoreactive cells within this population.
Although BAFF and its receptors have been associated mostly with B cell responses, we showed that BAFF also had profound effects on T cell costimulation, occurring through BAFF-R. However, immobilized BAFF rather than soluble BAFF provided these costimulatory signals to T cells (this report and Ref. 22) suggesting that BAFF signaling through BAFF-R on T cells requires membrane expression by APC. It is also conceivable that APCs immobilize and present soluble BAFF. BAFF-R has been identified as a survival receptor for B cells and it may serve a similar role for T cells, rather than act as a classic costimulatory receptor. For instance, signals through BAFF-R increase Bcl-2 expression in T cells (Fig. 3) as they do for B cells (37), which may result in enhanced basal T cell survival, particularly by BAFF-R+ T cells such as effector and central memory subsets. Enhanced T cell survival would then augment the number of T cells capable of activation. The activity of BAFF as an important component of costimulation (or survival factor) for T cell proliferation is intriguing because of the very high levels of BAFF in inflammatory lesions and blood of certain patients with autoimmune diseases (7, 9, 10, 46), although whether BAFF in such patients affects T cell biology is uncertain. Interestingly, the cell types that are expanded in BAFF transgenic mice include mature B cells, splenic T2 and MZ B cells, and also effector memory T cells (4, 33). Our in vivo data has also shown that BAFF enhances the delayed-type hypersensitivity reaction, which is a classical T-dependent immune response (our unpublished data). Taken together, these results clearly indicate that BAFF is not only an important B cell factor; it is also a critical factor for T cell responses. The reason why only immobilized BAFF costimulated T cells is unresolved; it is possible that immobilization of BAFF on the plastic plate reproduces elements of membrane expression by APCs. A final feature of BAFF-R worthy of comment is that BAFF-R binds BAFF but not APRIL, and so the reported effects of APRIL on T cells (25) presumably occur through an unidentified receptor, or through indirect mechanisms.
BAFF receptors were regulated during B cell differentiation to GC cells. The most obvious expression of BCMA was by B cells in tonsil with a phenotype consistent with GC B cells, i.e., CD38+, CD27+, CD39–, and IgM– (47, 48). BAFF is important for the GC reaction, because blocking BAFF in vivo attenuates the GC reaction (49), and those GCs that do form in BAFF-deficient mice have impaired maturation and function (50). BAFF-R was also expressed on GC B cells, but at lower levels compared with mature B cells. Interestingly, TACI was largely absent from GC B cells, suggesting that its proposed role as a negative regulator of B cell activation (21, 35) does not extend to the GC reaction. Its loss from GC B cells would be consistent with the down-regulation by GC B cells of another inhibitory receptor, leukocyte-associated immunoglobulin-like receptor-1 (51) and the phosphatase Src homology 2-containing protein tyrosine phosphatases 1 (52). This would serve to limit the function of inhibitory receptors, and thus reduce the threshold for activation and proliferation in the course of B cell selection and differentiation within GCs. TACI mAb stained subsets of mature naive B cells, memory B cells, and activated B cells, suggesting that TACI regulates the responses of each these B cell subsets, but not GC B cells. The acquisition of BCMA by GC B cells (and plasmablasts) (28) presumably plays a role in regulating their survival, although the high expression of BAFF-R, albeit at lower levels compared with circulating B cells, implies a role for this receptor as well. The reason for BCMA up-regulation on GC cells is uncertain, but one consequence might be the acquired ability to signal in response to APRIL as well as BAFF.
The basis for the development of BAFF-associated autoimmune diseases is uncertain, but several possibilities exist. One is that during splenic maturation, BAFF corrupts B cell tolerance (33), possibly through excessive BAFF signaling through BAFF-R (17). However, BAFF receptors, particularly BAFF-R, are expressed abundantly at most stages of peripheral B cell differentiation. The GC reaction is another conceivable point where newly generated B cells with novel BCR specificities might escape tolerance induction, particularly in the presence of excess BAFF. However, in a recent study from our laboratory, TNF–/– mice that lack GC, when crossed to BAFF transgenic mice, still developed autoimmune disorders, indicating that corruption of tolerance in BAFF transgenic mice occurs independently of the GC reaction (36). BAFF might also costimulate autoreactive T cells. Blocking BAFF (and/or APRIL) severely inhibits inflammation in a mouse model of rheumatoid arthritis vivo (24); however, whether this effect is through T or B cells is uncertain. Indeed the relative contribution of T cells, B cells, and macrophages to disease pathogenesis in many autoimmune diseases is still unclear. In any event, our results clearly establish BAFF-R as the predominant BAFF receptor for circulating T and B cell responses, with BCMA and TACI showing much more restricted expression patterns and, by inference, having more specialized functional roles in B cell responses. Thus BAFF-R, as a widely expressed receptor of important functional relevance for T and B cell responses, represents an attractive target for intervention in autoimmune diseases.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 L.G.N. and A.S. contributed equally to this work.
3 Address correspondence and reprint requests to Dr. Charles R. Mackay, Arthritis and Inflammation Research Program, The Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia. E-mail address: c.mackay{at}garvan.org.au
4 Abbreviations used in this paper: BAFF, B cell-activating factor belonging to the TNF family; BCMA, B cell maturation Ag; h., human; hIgG, human IgG; GC, germinal center; m., mouse; MZ, marginal zone; RBL, rat basophilic leukemia; TACI, transmembrane activator and calcium modulator and cyclophilin ligand interactor; T1, transitional type 1; T2, transitional type 2; WT, wild type; APRIL, a proliferation-inducing ligand.
Received for publication March 15, 2004. Accepted for publication May 14, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  K. L. Hoek, G. Carlesso, E. S. Clark, and W. N. Khan Absence of Mature Peripheral B Cell Populations in Mice with Concomitant Defects in B Cell Receptor and BAFF-R Signaling J. Immunol., November 1, 2009; 183(9): 5630 - 5643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Warnatz, U. Salzer, M. Rizzi, B. Fischer, S. Gutenberger, J. Bohm, A.-K. Kienzler, Q. Pan-Hammarstrom, L. Hammarstrom, M. Rakhmanov, et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans PNAS, August 18, 2009; 106(33): 13945 - 13950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Tertilt, J. Joh, A. Krause, P. Chou, K. Schneeweiss, R. G. Crystal, and S. Worgall Expression of B-Cell Activating Factor Enhances Protective Immunity of a Vaccine against Pseudomonas aeruginosa Infect. Immun., July 1, 2009; 77(7): 3044 - 3055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Marino, J. Villanueva, S. Walters, D. Liuwantara, F. Mackay, and S. T. Grey CD4+CD25+ T-Cells Control Autoimmunity in the Absence of B-Cells Diabetes, July 1, 2009; 58(7): 1568 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Krystufkova, T Vallerskog, S B. Helmers, H Mann, I Putova, J Belacek, V Malmstrom, C Trollmo, J Vencovsky, and I E Lundberg Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies Ann Rheum Dis, June 1, 2009; 68(6): 836 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gupta, S. R. Dillon, S. C. Ziesmer, A. L. Feldman, T. E. Witzig, S. M. Ansell, J. R. Cerhan, and A. J. Novak A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation Blood, May 21, 2009; 113(21): 5206 - 5216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Kimberley, L. van Bostelen, K. Cameron, G. Hardenberg, J. A. Marquart, M. Hahne, and J. P. Medema The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking FASEB J, May 1, 2009; 23(5): 1584 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Di Carlo, T. D'Antuono, P. Pompa, R. Giuliani, S. Rosini, L. Stuppia, P. Musiani, and C. Sorrentino The Lack of Epithelial Interleukin-7 and BAFF/BLyS Gene Expression in Prostate Cancer as a Possible Mechanism of Tumor Escape from Immunosurveillance Clin. Cancer Res., May 1, 2009; 15(9): 2979 - 2987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Salzer, C. Bacchelli, S. Buckridge, Q. Pan-Hammarstrom, S. Jennings, V. Lougaris, A. Bergbreiter, T. Hagena, J. Birmelin, A. Plebani, et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes Blood, February 26, 2009; 113(9): 1967 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Walters, K. E. Webster, A. Sutherland, S. Gardam, J. Groom, D. Liuwantara, E. Marino, J. Thaxton, A. Weinberg, F. Mackay, et al. Increased CD4+Foxp3+ T Cells in BAFF-Transgenic Mice Suppress T Cell Effector Responses J. Immunol., January 15, 2009; 182(2): 793 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Stefanich, S. Ren, D. M. Danilenko, A. Lim, A. Song, S. Iyer, and P. J. Fielder Evidence for an Asialoglycoprotein Receptor on Nonparenchymal Cells for O-Linked Glycoproteins J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 308 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C B Driver, M Ishimori, and M H Weisman The B cell in systemic lupus erythaematosus: a rational target for more effective therapy Ann Rheum Dis, October 1, 2008; 67(10): 1374 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Lai Kwan Lam, O. King Hung Ko, B.-J. Zheng, and L. Lu Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis PNAS, September 30, 2008; 105(39): 14993 - 14998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hardenberg, L. Fernandez, J. Hendriks, K. Chebli, C. Jacquet, M. Sitbon, M. Hahne, and J. P. Medema APRIL facilitates viral-induced erythroleukemia but is dispensable for T cell immunity and lymphomagenesis J. Leukoc. Biol., August 1, 2008; 84(2): 380 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kanswal, N. Katsenelson, A. Selvapandiyan, R. J. Bram, and M. Akkoyunlu Deficient TACI Expression on B Lymphocytes of Newborn Mice Leads to Defective Ig Secretion in Response to BAFF or APRIL J. Immunol., July 15, 2008; 181(2): 976 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Chang, S. A. Mihalcik, and D. F. Jelinek B Lymphocyte Stimulator Regulates Adaptive Immune Responses by Directly Promoting Dendritic Cell Maturation J. Immunol., June 1, 2008; 180(11): 7394 - 7403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Nestorov, A. Munafo, O. Papasouliotis, and J. Visich Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis J. Clin. Pharmacol., April 1, 2008; 48(4): 406 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Benson, S. R. Dillon, E. Castigli, R. S. Geha, S. Xu, K.-P. Lam, and R. J. Noelle Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL J. Immunol., March 15, 2008; 180(6): 3655 - 3659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Badr, G. Borhis, E. A. Lefevre, N. Chaoul, F. Deshayes, V. Dessirier, G. Lapree, A. Tsapis, and Y. Richard BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells Blood, March 1, 2008; 111(5): 2744 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bossen, T. G. Cachero, A. Tardivel, K. Ingold, L. Willen, M. Dobles, M. L. Scott, A. Maquelin, E. Belnoue, C.-A. Siegrist, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts Blood, February 1, 2008; 111(3): 1004 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Darce, B. K. Arendt, X. Wu, and D. F. Jelinek Regulated Expression of BAFF-Binding Receptors during Human B Cell Differentiation J. Immunol., December 1, 2007; 179(11): 7276 - 7286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Y. Lin, Q. Gong, D. Seshasayee, Z. Lin, Q. Ou, S. Ye, E. Suto, J. Shu, W. Pun Lee, C.-W. V. Lee, et al. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade Blood, December 1, 2007; 110(12): 3959 - 3967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kuchen, R. Robbins, G. P. Sims, C. Sheng, T. M. Phillips, P. E. Lipsky, and R. Ettinger Essential Role of IL-21 in B Cell Activation, Expansion, and Plasma Cell Generation during CD4+ T Cell-B Cell Collaboration J. Immunol., November 1, 2007; 179(9): 5886 - 5896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kaur, S. Chowdhury, N. S. Greenspan, and J. R. Schreiber Decreased expression of tumor necrosis factor family receptors involved in humoral immune responses in preterm neonates Blood, October 15, 2007; 110(8): 2948 - 2954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P. Shinners, G. Carlesso, I. Castro, K. L. Hoek, R. A. Corn, R. L. Woodland, M. L. Scott, D. Wang, and W. N. Khan Bruton's Tyrosine Kinase Mediates NF-{kappa}B Activation and B Cell Survival by B Cell-Activating Factor Receptor of the TNF-R Family J. Immunol., September 15, 2007; 179(6): 3872 - 3880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Groom, C. A. Fletcher, S. N. Walters, S. T. Grey, S. V. Watt, M. J. Sweet, M. J. Smyth, C. R. Mackay, and F. Mackay BAFF and MyD88 signals promote a lupuslike disease independent of T cells J. Exp. Med., August 6, 2007; 204(8): 1959 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sellam, C. Miceli-Richard, J.-E. Gottenberg, M. Ittah, F. Lavie, C. Lacabaratz, N. Gestermann, A. Proust, O. Lambotte, and X. Mariette Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus Ann Rheum Dis, June 1, 2007; 66(6): 790 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Darce, B. K. Arendt, S. K. Chang, and D. F. Jelinek Divergent Effects of BAFF on Human Memory B Cell Differentiation into Ig-Secreting Cells J. Immunol., May 1, 2007; 178(9): 5612 - 5622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lavie, C. Miceli-Richard, M. Ittah, J. Sellam, J.-E. Gottenberg, and X. Mariette Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production Ann Rheum Dis, May 1, 2007; 66(5): 700 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kawasaki, N. Tsuchiya, J. Ohashi, Y. Murakami, T. Fukazawa, M. Kusaoi, S. Morimoto, K. Matsuta, H. Hashimoto, Y. Takasaki, et al. Role of APRIL (TNFSF13) polymorphisms in the susceptibility to systemic lupus erythematosus in Japanese Rheumatology, May 1, 2007; 46(5): 776 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Kuo, A. L. Shaffer, J. Haddad Jr., Y. S. Choi, L. M. Staudt, and K. Calame Repression of BCL-6 is required for the formation of human memory B cells in vitro J. Exp. Med., April 16, 2007; 204(4): 819 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Hondowicz, S. T. Alexander, W. J. Quinn III, A. J. Pagan, M. H. Metzgar, M. P. Cancro, and J. Erikson The role of BLyS/BLyS receptors in anti-chromatin B cell regulation Int. Immunol., April 1, 2007; 19(4): 465 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sakurai, H. Hase, Y. Kanno, H. Kojima, K. Okumura, and T. Kobata TACI regulates IgA production by APRIL in collaboration with HSPG Blood, April 1, 2007; 109(7): 2961 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ettinger, G. P. Sims, R. Robbins, D. Withers, R. T. Fischer, A. C. Grammer, S. Kuchen, and P. E. Lipsky IL-21 and BAFF/BLyS Synergize in Stimulating Plasma Cell Differentiation from a Unique Population of Human Splenic Memory B Cells J. Immunol., March 1, 2007; 178(5): 2872 - 2882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kothlow, I. Morgenroth, Y. Graef, K. Schneider, I. Riehl, P. Staeheli, P. Schneider, and B. Kaspers Unique and conserved functions of B cell-activating factor of the TNF family (BAFF) in the chicken Int. Immunol., February 1, 2007; 19(2): 203 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Rolph, T. R. Young, B. O. V. Shum, C. Z. Gorgun, C. Schmitz-Peiffer, I. A. Ramshaw, G. S. Hotamisligil, and C. R. Mackay Regulation of Dendritic Cell Function and T Cell Priming by the Fatty Acid-Binding Protein aP2 J. Immunol., December 1, 2006; 177(11): 7794 - 7801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Lee, S. G. Hymowitz, H. J. Wallweber, N. C. Gordon, K. L. Billeci, S.-P. Tsai, D. M. Compaan, J. Yin, Q. Gong, R. F. Kelley, et al. Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells Blood, November 1, 2006; 108(9): 3103 - 3111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Chang, B. K. Arendt, J. R. Darce, X. Wu, and D. F. Jelinek A role for BLyS in the activation of innate immune cells Blood, October 15, 2006; 108(8): 2687 - 2694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Huntington, R. Tomioka, C. Clavarino, A. M. Chow, D. Linares, P. Mana, J. Rossjohn, T. G. Cachero, F. Qian, S. L. Kalled, et al. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses Int. Immunol., October 1, 2006; 18(10): 1473 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. O. Jacob, L. Pricop, C. Putterman, M. N. Koss, Y. Liu, M. Kollaros, S. A. Bixler, C. M. Ambrose, M. L. Scott, and W. Stohl Paucity of Clinical Disease despite Serological Autoimmunity and Kidney Pathology in Lupus-Prone New Zealand Mixed 2328 Mice Deficient in BAFF J. Immunol., August 15, 2006; 177(4): 2671 - 2680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Vugmeyster, D. Seshasayee, W. Chang, A. Storn, K. Howell, S. Sa, T. Nelson, F. Martin, I. Grewal, E. Gilkerson, et al. A Soluble BAFF Antagonist, BR3-Fc, Decreases Peripheral Blood B Cells and Lymphoid Tissue Marginal Zone and Follicular B Cells in Cynomolgus Monkeys Am. J. Pathol., February 1, 2006; 168(2): 476 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chtanova, R. Newton, S. M. Liu, L. Weininger, T. R. Young, D. G. Silva, F. Bertoni, A. Rinaldi, S. Chappaz, F. Sallusto, et al. Identification of T Cell-Restricted Genes, and Signatures for Different T Cell Responses, Using a Comprehensive Collection of Microarray Datasets J. Immunol., December 15, 2005; 175(12): 7837 - 7847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wheway, C. R. Mackay, R. A. Newton, A. Sainsbury, D. Boey, H. Herzog, and F. Mackay A fundamental bimodal role for neuropeptide Y1 receptor in the immune system J. Exp. Med., December 5, 2005; 202(11): 1527 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zheng, S. Gallucci, J. P. Gaughan, J. A. Gross, and M. Monestier A Role for B Cell-Activating Factor of the TNF Family in Chemically Induced Autoimmunity J. Immunol., November 1, 2005; 175(9): 6163 - 6168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yang, H. Hase, D. Legarda-Addison, L. Varughese, B. Seed, and A. T. Ting B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells J. Immunol., September 1, 2005; 175(5): 2814 - 2824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, K.-H. Ko, Q. L. K. Lam, C. K. C. Lo, G. Srivastava, B. Zheng, Y.-L. Lau, and L. Lu Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis Int. Immunol., August 1, 2005; 17(8): 1081 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Gavin, B. Duong, P. Skog, D. Ait-Azzouzene, D. R. Greaves, M. L. Scott, and D. Nemazee {Delta}BAFF, a Splice Isoform of BAFF, Opposes Full-Length BAFF Activity In Vivo in Transgenic Mouse Models J. Immunol., July 1, 2005; 175(1): 319 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, C.-S. Park, S.-O. Yoon, L. Li, Y.-M. Hsu, C. Ambrose, and Y. S. Choi BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors Int. Immunol., June 1, 2005; 17(6): 779 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Sims, R. Ettinger, Y. Shirota, C. H. Yarboro, G. G. Illei, and P. E. Lipsky Identification and characterization of circulating human transitional B cells Blood, June 1, 2005; 105(11): 4390 - 4398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ingold, A. Zumsteg, A. Tardivel, B. Huard, Q.-G. Steiner, T. G. Cachero, F. Qiang, L. Gorelik, S. L. Kalled, H. Acha-Orbea, et al. Identification of proteoglycans as the APRIL-specific binding partners J. Exp. Med., May 2, 2005; 201(9): 1375 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. R. Sutherland, L. G. Ng, C. A. Fletcher, B. Shum, R. A. Newton, S. T. Grey, M. S. Rolph, F. Mackay, and C. R. Mackay BAFF Augments Certain Th1-Associated Inflammatory Responses J. Immunol., May 1, 2005; 174(9): 5537 - 5544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Krumbholz, D. Theil, T. Derfuss, A. Rosenwald, F. Schrader, C.-M. Monoranu, S. L. Kalled, D. M. Hess, B. Serafini, F. Aloisi, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma J. Exp. Med., January 18, 2005; 201(2): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
), and lack of costimulation of A/WySnJ T cells (
). T cells obtained from A/WySnJ mice responded well to anti-CD28 (2 µg/ml) costimulation. These T cells were purified from spleens by magnetic sorting, and cultures were activated with 1 µg/ml plate-bound anti-CD3, ± an optimal amount of plate-bound BAFF (4 µg/ml). E, T cells form TACI–/– mice, stimulated with anti-CD3 ± BAFF (
). h.BAFF-R Fc was used as a positive BAFF-neutralizing agent (
)
